Fifty-five years after the Controlled Substances Act of 1970 relegated psilocybin to Schedule I status—placing it alongside heroin as a substance with "no accepted medical use"—the narrative surrounding the compound is undergoing a radical, historic shift. As the United States moves toward the potential FDA approval of synthetic psilocybin for treatment-resistant depression, the conversation has moved from the laboratory to the boardroom.
For industry pioneers like Compass Pathways, whose proprietary synthetic psilocybin, COMP360, has successfully hit its primary endpoints in two Phase 3 trials, the finish line is in sight. Yet, as the regulatory pathway clears, a new, critical challenge emerges: how to build a sustainable, insurable ecosystem around a substance that has spent over half a century in the shadows of prohibition.
The Regulatory Path to Commercialization
The momentum behind psilocybin is no longer merely academic; it is bolstered by an unprecedented alignment of regulatory acceleration and executive mandate. Following Compass Pathways’ successful Phase 3 results, the company began filing its New Drug Application (NDA) on a rolling basis, a move greenlit by the FDA in April 2026.
This momentum was further catalyzed by the FDA’s decision to award COMP360 a Commissioner’s National Priority Voucher (CNPV). This designation is a powerful lever, potentially compressing the standard 10-to-12-month review process into a window as brief as one or two months. Simultaneously, the political landscape has shifted; in April 2026, President Trump issued an executive order directing federal agencies to accelerate the review and approval processes for psychedelic therapies aimed at addressing serious mental illness. While the 12-month approval window once projected by Secretary Robert F. Kennedy Jr. may be optimistic, industry analysts suggest a formal FDA decision could realistically arrive by late 2026 or early 2027.
Risk and Responsibility: The Underwriter’s Perspective
As these regulatory hurdles fall, the insurance sector is grappling with how to quantify risk in a field that lacks historical precedent. Jonathan Bound, product development lead at Relm Insurance—a firm that has been at the forefront of underwriting the burgeoning psychedelics sector—notes that the transition from a "fringe" treatment to a standardized pharmaceutical product creates a complex web of liability.
"The key question for us isn’t just about the molecule," Bound explains. "It’s about the infrastructure. We are looking at a system that requires a Risk Evaluation and Mitigation Strategy (REMS). While REMS are designed to protect the patient, they also create a rigid, documented set of obligations for the provider."
For an underwriter, a REMS program is a double-edged sword. On one hand, it provides a federal roadmap for safety, which helps in standardizing risk. On the other hand, it creates a "compliance trap." If a provider deviates from the federally prescribed protocols, they become inherently more vulnerable to litigation. "The insurer might not be liable for the failure of the REMS itself," Bound notes, "but we certainly have a duty to defend or indemnify providers against claims of negligence or professional misconduct that stem from a failure to follow those mandatory safety protocols."
Comparing Psilocybin to Existing Interventional Models
One of the most frequent comparisons in the industry is to Spravato (esketamine), which already operates under a REMS program with mandatory multi-hour monitoring. However, experts like Bound argue that psilocybin introduces unique variables that require a recalibration of insurance models.
The Challenge of Duration and Vulnerability
A psilocybin session is significantly longer than the standard two-hour interventional psychiatry window required for Spravato. This creates a longer period of "patient control," where the individual is in an altered, highly vulnerable state.
"When you extend the duration of a session to a full day," Bound says, "you aren’t just increasing the time the patient is in the clinic; you are increasing the window for potential liability events." These include:
- Boundary Violations: Risks related to the intense rapport and power dynamics inherent in psychedelic-assisted therapy.
- Patient Elopement: The increased risk of a patient leaving the premises while still under the influence.
- Psychological Destabilization: The need for higher-level emergency response protocols should a patient experience a severe adverse psychological reaction.
- Staffing Adequacy: The necessity for trained, specialized monitors present throughout the entire duration of the experience.
Building a Durable Market: Where the Money Moves
Relm Insurance, having already underwritten state-regulated psilocybin programs in Oregon and Colorado, is using that "real-world" data to inform its approach to the federal market. Bound emphasizes that while state-level programs provide some insight, FDA-approved pathways offer a more structured, albeit compliance-heavy, environment.
"An FDA-approved medication brings standardized dosing, clinical labeling, and clearly defined indications," Bound explains. "This allows us to move away from the uncertainty of state-run service centers toward a model where risk can be priced with much higher precision."
The Value Chain of Insurable Business
Over the next two to three years, Relm expects to see insurable business coalesce around specific pillars of the industry:
- Manufacturing and Distribution: Managing the risks inherent in producing a Schedule I (or rescheduled) controlled substance.
- Clinical Research Organizations (CROs): Insuring the trials themselves as they expand post-approval.
- Certified Treatment Sites: The physical infrastructure where administration occurs, focusing on premises liability and patient safety.
- Training Organizations: Insuring the educational entities that certify the facilitators and clinicians, a critical component of the risk-mitigation framework.
The "Concentration Risk" Fallacy
One common concern among investors is "concentration risk"—the idea that the intensive, site-specific nature of psilocybin therapy makes it inherently unscalable or too risky to insure. Bound pushes back against this notion.
"Longer sessions do not make a business model inherently harder to underwrite; they just make the underwriting process more granular," he says. "If the controls at a facility are standardized, auditable, and transparent, the risk becomes manageable. The danger arises only when the operating model is too inconsistent or too thinly funded to support the necessary safety overhead."
Implications: The Path to Sustainability
The success of the psilocybin industry will ultimately depend on whether the "post-approval ecosystem" can achieve financial and operational sustainability. The greatest threat to the market, according to Bound, is not the drug itself, but the possibility that the overhead costs—insurance, compliance, facility management, and specialized labor—make the treatment model prohibitively expensive or unsustainable.
"If the market develops around clear protocols and credible clinical governance, we can support it," Bound says. "But if the operating model remains too expensive to sustain or too inconsistent to provide quality care, the market will struggle to reach maturity."
As the industry stands on the precipice of a new era, the insurance sector is signaling that it is ready to participate, provided the industry focuses on the "boring" but essential work of building robust, compliant, and auditable infrastructure. The "trip," as it were, is being insured—but only if the flight plan is filed, the crew is certified, and the emergency protocols are fully documented. The transformation of psilocybin from a prohibited substance to a regulated medicine is a monumental undertaking, but one that is increasingly defined by the practicalities of modern risk management.
About the Author
